Biogen confirmed as under Dutch dominance-abuse probe over MS drugs
( November 6, 2026, 12:46 GMT | Official Statement) -- MLex Summary: The Dutch antitrust authority is investigating Biogen to determine whether the prescription drug manufacturer abused its market power in relation to multiple sclerosis treatment, it confirmed on Friday. The watchdog is assessing how Biogen makes its anti-JVC blood test Stratify, which is exclusively available to patients treated with Biogen drug Tysabri or those considering treatment with it, available in the Netherlands.Statement follows. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.